SteriPort delays weigh Q1; strong multi-year visibility

Delivered ₹68.8 Cr, +5.4% YoY

Implied ₹15 Cr EBITDA on ₹68.8 Cr revenue = 21.8% margin

PAT ₹3.3 Cr, -5.6% YoY and -40.2% QoQ; NPM 4.8% (constrained)

44% of ₹68.8 Cr = ~₹30 Cr; plausible

FDA approval Aug 6, commercial production end August expected; ₹80-85 Cr guidance deferred by one quarter

Civil construction delay shifted commissioning from Q1 to Q2 FY27 (4-5 month slip). Guidance for ₹80-85 Cr expansion contribution deferred by one quarter but not withdrawn.

Polymer spike + overhead absorption kept margins flat. Prior guidance for 24-25% margin improvement deferred to FY28 post-SteriPort ramp and solar benefit realization.

Solar capex debt (₹75 lakh/month savings) added incremental interest this quarter; will reduce in FY28 as capex cycle winds down.

One-time overhead and depreciation pressures outweighed revenue growth. Profit recovery expected Q2+ as SteriPort ramps and overheads are absorbed.

Inhalation product to launch Sept 2026 (ahead of Mar 2027 facility commissioning). Portfolio depth increases odds of commercial success and export traction.

₹120 Cr is annualized number; within 12 months of late-August commissioning, should achieve that run-rate.

4-5% expansion including ₹9 Cr solar benefit, plus overhead absorption on SteriPort Line 3 (dedicated 500ml platform).

Polymer spike 70-80% for ~2 months (largely passed through at ₹1.50/unit); main pressure was pre-commissioning overheads for SteriPort.

FAT scheduled USA Nov 2026; facility at site by December; operational by Feb-March 2027 (no major civil work needed).

FY27 ~₹370 Cr (baseline) + SteriPort ₹70 Cr (7 months) ~₹440 Cr. FY28 ₹425 Cr at full utilization; 25-26% EBITDA margins both years.

Polymer prices linked to crude oil; spike was 2-month anomaly. Prices have softened and normalized; unlikely further spikes.

Opposite: SteriPort realization higher due to high-value formulations (not plain IV fluids). Formulation product mix drives higher net revenue value.

Polymer impact ₹2.25/unit; price increase ₹1.50/unit. Shortfall absorbed this quarter; recovery will spill into 2 quarters as cost normalizes but price sticks.

SVP 90% export; 60%+ from advanced/semi-advanced markets. Amanta has prior diluent/OTC export to Australia, Canada, UK. First logical step post-SVP is ophthalmics for PIC markets.

WC cycle constrained by 15-25 day quarantine (export). D/E will reduce ₹30-35 Cr annually; solar capex added debt but is high-return investment (₹75 lakh/month savings).

20-product inhalation/ophthalmics pipeline (18-month completion). Exploring non-plastic packaging (glass, cartridges) for future FY27+ initiatives. Staying focused on sterile dosage forms.

No numbers at call; dedicated F&D team 8-10 people + 3-4 regulatory affairs for advanced/semi-advanced markets planned. Will quantify and circulate separately.

SteriPort Line 3: ₹90 Cr total, ₹80 Cr spent. SVP: ₹30 Cr total, ₹7 Cr spent; remaining FY27-28.

Broadly correct. SVP ROCE 14-15% (lower asset turns). Both in-line with or slightly better than industry peers.

FY27 ₹21 Cr annualized; FY28 ₹18-19 Cr (debt reduction kicks in post-capex cycle)

SteriPort Line 3 FDA-approved; commissioning late August. Baseline ₹370 Cr from existing portfolio assumed. SVP not included (not yet live).

Assumes SteriPort Line 3 at full 12 Cr bottle/year capacity; ₹120 Cr annualized revenue from new line. Existing portfolio stable. SVP ramp-up timing uncertain.

Driven by (a) SteriPort Line 3 overhead absorption & dedicated platform leverage; (b) solar capex ₹9 Cr annual savings; (c) improved product mix toward high-value therapies

Includes ₹9 Cr solar benefit + product mix shift + operational leverage. Assumes full SteriPort ramp and no major input cost shocks.

Completion late August 2026. Additional depreciation ₹4.5 Cr annually from this line.

FAT USA Nov 2026; deployment Dec 2026; commissioning March 2027. No major civil work (lower execution risk).

10.8 MW plant operational; debt-financed but high ROI (₹75 lakh/month savings = 9% IRR).

Line 3 commissioning targeted late August; depends on FDA inspection (scheduled Aug 21) clearance. Any delay pushes revenue ramp into Q3, compressing FY27 guidance.

SteriPort Line 3 originally targeted Q1 FY27; delayed to Q2 (4-5 month slip). If delayed further, ₹80-85 Cr prior guidance for 'first three quarters' becomes unachievable.

Manpower for SteriPort Line 3 and SVP hired pre-commissioning. Overhead absorbed into Q1 cost structure without offsetting revenue. Magnitude not disclosed but sufficient to trigger 'cost pressures' narrative.

Polymer spiked 70-80% for ~2 months in Q1; absorbed cost ₹2.25/unit but passed through only ₹1.50/unit (67% recovery). Shortfall may persist if crude oil prices spike again.

SVP facility March 2027 commissioning assumes on-time FAT (USA Nov 2026). 20-product pipeline (inhalation, ophthalmics) requires advanced-market regulatory approvals (UK, EU, Australia, Canada). First inhalation product Sept 2026 launch is achievable but unproven at scale.

SteriPort faces competition from Otsuka (Japan MNC), Fresenius Kabi (German MNC), B. Braun, Aculife. MNCs have deeper R&D, global distribution, pricing power. Amanta's moat (ISBM technology, first-mover in India) may not hold against aggressive competition.

Debt-to-equity 1.06; additional debt for solar capex. If interest rates spike or debt covenant pressure hits, refinancing may become constrained.